Lucid Diagnostics (NASDAQ:LUCD – Get Rating) will announce its earnings results before the market opens on Tuesday, May 16th. Investors interested in participating in the company’s conference call can do so using this link.
Lucid Diagnostics Trading Up 2.7 %
NASDAQ:LUCD opened at $1.53 on Friday. Lucid Diagnostics has a twelve month low of $1.11 and a twelve month high of $3.64. The company has a market cap of $66.39 million, a price-to-earnings ratio of -1.06 and a beta of 2.04. The stock has a fifty day simple moving average of $1.48 and a 200-day simple moving average of $1.54.
Institutional Trading of Lucid Diagnostics
Several institutional investors and hedge funds have recently made changes to their positions in LUCD. Vanguard Group Inc. raised its holdings in shares of Lucid Diagnostics by 11.3% in the third quarter. Vanguard Group Inc. now owns 319,366 shares of the company’s stock valued at $489,000 after acquiring an additional 32,305 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Lucid Diagnostics by 18.7% in the first quarter. BlackRock Inc. now owns 67,565 shares of the company’s stock valued at $227,000 after acquiring an additional 10,636 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in shares of Lucid Diagnostics in the first quarter valued at about $209,000. State Street Corp raised its holdings in shares of Lucid Diagnostics by 24.4% in the first quarter. State Street Corp now owns 56,693 shares of the company’s stock valued at $190,000 after acquiring an additional 11,121 shares in the last quarter. Finally, Verition Fund Management LLC grew its stake in Lucid Diagnostics by 29.2% in the second quarter. Verition Fund Management LLC now owns 46,709 shares of the company’s stock valued at $106,000 after purchasing an additional 10,543 shares during the last quarter. 5.89% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Lucid Diagnostics Company Profile
Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.
- Get a free copy of the StockNews.com research report on Lucid Diagnostics (LUCD)
- MarketBeat Week in Review – 5/8 – 5/12
- An Updraft Is Brewing For DraftKings
- PepsiCo Hits “Sweet Spot” For APAC Growth, Macros Agree
- High-Risk Mullen Automotive Continues To Build Momentum
- 3 Recession-Proof Stocks With Nice Dividends
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.